Summary

TARGET-IBD is a 5-year, longitudinal, observational study of adult and pediatric patients (age 2 and above) being managed for Inflammatory Bowel Disease (IBD) in usual clinical practice. TARGET-IBD will create a research registry of patients with IBD within academic and community real-world practices in order to assess the safety and effectiveness of current and future therapies.

Age: 2 Years and older

Gender: All

Start Date: 07/24/2017

Primary Completion Date (Estimated): 03/01/2027

Study Completion Date (Estimated): 03/01/2027

Accepts Healthy Volunteers: No

Trial Purpose and Description

Eligibility Criteria

Age: 2 Years and older

Gender: All

Accepts Healthy Volunteers: No

Inclusion criteria:

1. Adults and children (age 2 or older) with a diagnosis of Crohn's disease (CD), Ulcerative colitis (UC), or Indeterminate colitis (IBDU) having been prescribed any IBD treatment (initial or subsequent) outside of a clinical trial.

2. Have plans for future visits at the site for continued management of IBD.

Exclusion criteria:

1. Inability to provide written informed consent/assent.

2. Being enrolled in any interventional study or trial for IBD treatment. Note: Patient may be enrolled in other registries or studies where IBD treatment outcomes are observed and/or reported (such as center-based registries).

3. Prior total abdominal colectomy for UC or IBDU.